Rankings
▼
Calendar
MDGL FY 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$958M
+432.1% YoY
Gross Profit
$902M
94.1% margin
Operating Income
-$300M
-31.3% margin
Net Income
-$288M
-30.1% margin
EPS (Diluted)
$-12.85
Cash Flow
Operating Cash Flow
-$190M
Free Cash Flow
-$190M
Stock-Based Comp.
$98M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$657M
Stockholders' Equity
$603M
Cash & Equivalents
$199M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$958M
$180M
+432.1%
Gross Profit
$902M
$174M
+418.8%
Operating Income
-$300M
-$498M
+39.7%
Net Income
-$288M
-$466M
+38.1%
← Q4 2024
All Quarters
Q1 2025 →